Optimizing thiopurine therapy in inflammatory bowel disease
- PMID: 20949566
- DOI: 10.1002/ibd.21494
Optimizing thiopurine therapy in inflammatory bowel disease
Abstract
Despite recent advances, the therapeutic armamentarium for inflammatory bowel disease (IBD) is still limited. In addition, a step-up approach is recommended for most IBD patients. Thus, optimizing each medical therapy before switching to another drug class is the rule in clinical practice. Conventional therapies for IBD have not received the same amount of attention as biologic therapies over the last decade. However, due to their efficacy, safety, and low cost the thiopurine drugs azathioprine and 6-mercaptopurine remain the backbone of therapy for IBD. Pharmacogenomic advances and increased knowledge of their metabolism are allowing dosage optimization. Herein, after describing the pharmacogenetics and pharmacokinetics of thiopurines, we will discuss how to optimize thiopurine therapy. We will then underscore the need to take into account safety issues when optimizing thiopurine treatment.
Copyright © 2010 Crohn's & Colitis Foundation of America, Inc.
Similar articles
-
[Optimized thiopurine treatment in chronic inflammatory bowel disease].Ugeskr Laeger. 2014 May 26;176(22):V01140019. Ugeskr Laeger. 2014. PMID: 25352005 Review. Danish.
-
Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.Expert Opin Drug Saf. 2008 Sep;7(5):607-16. doi: 10.1517/14740338.7.5.607. Expert Opin Drug Saf. 2008. PMID: 18759713 Review.
-
Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.Inflamm Bowel Dis. 2015 Feb;21(2):445-52. doi: 10.1097/MIB.0000000000000197. Inflamm Bowel Dis. 2015. PMID: 25248004 Review.
-
Optimizing the therapeutic potential of azathioprine/6-mercaptopurine in the treatment of inflammatory bowel disease.J Clin Gastroenterol. 2003 May-Jun;36(5):379-81. doi: 10.1097/00004836-200305000-00001. J Clin Gastroenterol. 2003. PMID: 12702974 No abstract available.
-
Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease.Ther Drug Monit. 2016 Oct;38(5):621-7. doi: 10.1097/FTD.0000000000000326. Ther Drug Monit. 2016. PMID: 27465973 Clinical Trial.
Cited by
-
Pancreatitis associated with azathioprine and 6-mercaptopurine use in Crohn's disease: a systematic review.Frontline Gastroenterol. 2020 Jun 11;12(5):423-436. doi: 10.1136/flgastro-2020-101405. eCollection 2021. Frontline Gastroenterol. 2020. PMID: 35401955 Free PMC article.
-
Examining systemic steroid Use in older inflammatory bowel disease patients using hurdle models: a cohort study.BMC Pharmacol Toxicol. 2015 Dec 8;16:34. doi: 10.1186/s40360-015-0034-9. BMC Pharmacol Toxicol. 2015. PMID: 26643112 Free PMC article.
-
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?Nat Rev Gastroenterol Hepatol. 2013 Jun;10(6):345-51. doi: 10.1038/nrgastro.2013.31. Epub 2013 Mar 5. Nat Rev Gastroenterol Hepatol. 2013. PMID: 23458890 Review.
-
Clinical Variables as Predictors of First Relapse in Pediatric Crohn's Disease.Cureus. 2019 Jun 24;11(6):e4980. doi: 10.7759/cureus.4980. Cureus. 2019. PMID: 31467814 Free PMC article.
-
Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity.Pediatr Blood Cancer. 2020 Nov;67(11):e28360. doi: 10.1002/pbc.28360. Epub 2020 Sep 10. Pediatr Blood Cancer. 2020. PMID: 32909665 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources